GLP-1 Receptor Agonist Safety: Warnings, Contraindications & Drug Interactions

GLP-1 receptor agonists (GLP-1 RAs) — including semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and the dual agonist tirzepatide (Mounjaro, Zepbound) — carry a meaningful safety profile that every researcher and patient should understand before use. This guide synthesizes the FDA prescribing information for Ozempic and Wegovy alongside the broader class literature.

Black-Box Warning: Thyroid C-Cell Tumors

All GLP-1 RAs approved in the United States carry a black-box warning regarding thyroid C-cell tumors. In rodent studies (rats and mice), liraglutide and semaglutide caused dose-dependent and treatment-duration-dependent increases in thyroid C-cell adenomas and carcinomas at clinically relevant exposures. The relevance of these findings to humans is unknown, as human thyroid tissue expresses GLP-1 receptors at much lower levels than rodent thyroid.

Contraindications based on this warning: GLP-1 RAs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Patients should be counseled to report any symptoms that may indicate thyroid tumors, including a neck mass, dysphagia, hoarseness, or dyspnea.

Pancreatitis Risk

Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been reported with GLP-1 RAs. The FDA label for Ozempic and Wegovy states that GLP-1 RAs should be discontinued promptly if pancreatitis is suspected and should not be restarted if confirmed. Patients with a history of pancreatitis should use these agents with caution, and some clinicians consider prior pancreatitis a relative contraindication. Typical symptoms to monitor: persistent severe abdominal pain (often radiating to the back), nausea, and vomiting.

Gastrointestinal Side Effects and Titration

GI adverse events — nausea, vomiting, diarrhea, constipation, abdominal pain — are the most common reason for dose reduction or discontinuation. These are dose-dependent and most pronounced during dose escalation. Adherence to the prescribed titration schedule dramatically reduces GI burden: for semaglutide, this means four weeks at each dose step before advancing. Titrating more slowly than prescribed (e.g., staying at a step for 8 rather than 4 weeks) is a common clinical strategy for patients with significant GI intolerance.

Gastroparesis — slowing of gastric emptying to the point of causing persistent nausea, bloating, or vomiting unrelated to eating — has been reported as a rare but serious complication. Reports to the FDA’s FAERS database have increased since semaglutide’s widespread adoption, though causality is not established given the confounding of obesity itself with delayed gastric motility.

Contraindications and Drug Interactions

Absolute contraindications per FDA labeling: personal or family history of MTC; MEN2; known hypersensitivity to semaglutide or any excipient; pregnancy (weight loss is not recommended during pregnancy). Relative contraindications or cautions include: history of pancreatitis, severe renal impairment (for some agents), diabetic retinopathy (rapid glycemic improvement with semaglutide has been associated with worsening retinopathy in some diabetic patients), and severe GI disease.

Drug interactions: Semaglutide slows gastric emptying, which can reduce the rate (but not necessarily extent) of absorption of co-administered oral medications. This is particularly relevant for oral drugs with narrow therapeutic windows (e.g., warfarin, certain immunosuppressants, oral contraceptives). Insulin and insulin secretagogues (sulfonylureas): co-use with GLP-1 RAs increases hypoglycemia risk; dose reduction of the secretagogue is often required.

Cardiovascular and Renal Considerations

Unlike some older diabetes agents, semaglutide has demonstrated cardiovascular benefit: the SUSTAIN-6 trial showed significantly reduced rates of major adverse cardiovascular events (MACE) vs. placebo in patients with type 2 diabetes and high cardiovascular risk. GLP-1 RAs generally have a neutral-to-beneficial renal profile and are not dose-adjusted for mild-to-moderate renal impairment. Severe dehydration from GI side effects can, however, precipitate acute kidney injury — patients should be counseled to maintain hydration, especially during dose escalation.